What is Strategic Clinical Innovation Organization

  • The Strategic Clinical Innovation Organization (SCIO) concept provides biotech, pharmaceutical and device manufacturing companies with a cost-effective, customized approach to clinical development planning.This approach, pioneered by BBCR, aims to reduce the risks inherent in early stage clinical development. Such risks are particularly acute for:
  • Discovery drugs that offer the potential to suit multiple indications
  • Combination products
  • New drugs and devices

For each of these, changing regulatory requirements and rules require greater precision in clinical program development, from the outset of the developmental process.The SCIO concept, pioneered by BBCR, provides:

  • An early phase roadmap, to visualize goals, action plans and options
  • A strategic clinical plan that offers regulatory concurrence
  • Trial customization to suit innovative products, concepts, niche markets and regulatory requirements
  • Expert support on selection of indications
  • Optimized patient selection
  • An integrated approach to strategy, which maximizes the potential value of the product
  • Facilitated approach, to support management decision making and ongoing drug/device development

The SCIO concept is a bridge:

  • Linking preclinical data with market opportunities
  • Matching study endpoints with study objectives
  • Connecting product potential with actual treatment benefits

Together, this creates a cohesive Phase I/II development plan, offering thought-through FiM and PoC studies.

BBCR’s innovative approach hinges on Simplifying Clinical Research.

You Might Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *